VivoSim Labs, Inc. (VIVS)
NASDAQ: VIVS · Real-Time Price · USD
1.743
-0.004 (-0.21%)
Aug 8, 2025, 11:10 AM - Market open
Exscientia Employees
As of March 31, 2025, VivoSim Labs had 13 total employees, including 5 full-time and 8 part-time employees. The number of employees decreased by 7 or -35.00% compared to the previous year.
Employees
13
Change (1Y)
-7
Growth (1Y)
-35.00%
Revenue / Employee
$11,077
Profits / Employee
-$191,385
Market Cap
4.53M
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Mar 31, 2025 | 13 | -7 | -35.00% |
Mar 31, 2024 | 20 | -4 | -16.67% |
Mar 31, 2023 | 24 | 6 | 33.33% |
Mar 31, 2022 | 18 | 9 | 100.00% |
Mar 31, 2021 | 9 | 3 | 50.00% |
Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Mar 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 400,000 |
Johnson & Johnson | 138,100 |
Thermo Fisher Scientific | 125,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 92,900 |
Novo Nordisk | 77,349 |
Novartis AG | 75,883 |
Merck & Co. | 75,000 |
VIVS News
- 2 months ago - I Missed The Quantum Rally - I Won't Miss The Next One - Seeking Alpha
- 3 months ago - VivoSim's NAMKind™ Intestine Wins Blue Ribbon Award at Digestive Disease Week Conference - GlobeNewsWire
- 3 months ago - VivoSim Presents Best-in-Class Liver Toxicology Prediction Results at Digestive Disease Week Conference - GlobeNewsWire
- 3 months ago - VivoSim Announces Emergence from Stealth Mode To Provide Technologies for FDA Turn Away from Animal Models, $10B+ Market - GlobeNewsWire
- 3 months ago - VivoSim to Carry Forward Organovo 3D Bioprinting - GlobeNewsWire
- 4 months ago - Organovo Provides Update on Cash and Nasdaq Continued Listing Requirements - GlobeNewsWire
- 4 months ago - Organovo Provides Business Update - GlobeNewsWire
- 4 months ago - Organovo Announces Close of the Sale of FXR Program to Eli Lilly and Company - GlobeNewsWire